Is Oxford Immunotec Global PLC (OXFD)’s Fuel For Real? The Stock Just Increased Again

February 15, 2018 - By Nellie Frank

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It is negative, as 3 investors sold Oxford Immunotec Global PLC shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported.
Driehaus Cap Management Ltd Company owns 285,687 shares or 0.19% of their US portfolio. Tiaa Cref Invest Mngmt Limited Co holds 0% or 84,854 shares. Ardsley Advisory Ptnrs holds 15,000 shares or 0.03% of its portfolio. Waddell And Reed Fin reported 227,400 shares stake. Fosun Intll invested in 0.4% or 237,783 shares. D E Shaw & holds 0% or 57,641 shares. State Street Corporation holds 449,981 shares. New Leaf Venture Prns Ltd Liability Corp accumulated 852,497 shares or 6.65% of the stock. Credit Suisse Ag owns 14,898 shares. Penn Capital Mgmt has 0.19% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 158,603 shares. Grandeur Peak Global Advisors Ltd Liability Corporation, Us-based fund reported 700,778 shares. Alliancebernstein L P reported 14,700 shares or 0% of all its holdings. Scholtz & Ltd Liability Corp has 0.77% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Endurant Management Lp holds 731,509 shares or 3.72% of its portfolio. Voya Mngmt Ltd Liability Corporation owns 13,345 shares for 0% of their portfolio.

Since August 15, 2017, it had 0 insider buys, and 2 selling transactions for $970,393 activity. On Monday, October 2 Wrighton-Smith Peter sold $922,933 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) or 55,000 shares. Edwardson Peter sold 9,739 shares worth $157,171.

The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) is a huge mover today! The stock increased 3.66% or $0.42 during the last trading session, reaching $11.88. About 117,050 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since February 15, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.
The move comes after 5 months positive chart setup for the $304.78M company. It was reported on Feb, 15 by We have $12.47 PT which if reached, will make NASDAQ:OXFD worth $15.24M more.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.36 earnings per share, down 63.64 % or $0.14 from last year’s $-0.22 per share. After $-0.24 actual earnings per share reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 50.00 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. As per Thursday, October 19, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating by Cowen & Co given on Wednesday, September 27. On Tuesday, October 31 the stock rating was maintained by Robert W. Baird with “Buy”. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Piper Jaffray on Monday, January 8. The stock has “Buy” rating by Cowen & Co on Wednesday, August 16. Cowen & Co maintained the stock with “Buy” rating in Tuesday, October 31 report. The rating was maintained by Cowen & Co on Monday, January 22 with “Buy”. The firm has “Buy” rating given on Thursday, September 28 by BTIG Research. As per Wednesday, July 19, the company rating was maintained by Cowen & Co.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: which released: “Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release …” on February 13, 2018, also with their article: “Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent …” published on June 15, 2017, published: “Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full …” on January 08, 2018. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: and their article: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q3 2017 Results …” published on October 31, 2017 as well as‘s news article titled: “Oxford Immunotec, Qiagen settle patent litigation” with publication date: December 15, 2017.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $304.78 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.